C8191ZZ
Planar Nuclear Medicine Imaging Lacrimal Ducts, Bilateral to None with None, Technetium 99m (Tc-99m) Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | C Nuclear Medicine |
| Body System | 8 Eye |
| Operation | 1 Planar Nuclear Medicine Imaging |
| Body Part | 9 Lacrimal Ducts, Bilateral |
| Approach | 1 Technetium 99m (Tc-99m) |
| Device | Z None |
| Qualifier | Z None |
Operation Definition
Introduction of radioactive materials into the body for single plane display of images developed from the capture of radioactive emissions
Procedure Overview
This family covers planar nuclear medicine imaging of the eye, a diagnostic study in which a radioactive tracer is introduced into the body and a gamma camera captures a single flat image of the emissions concentrating in ocular tissue. It is used far less often than imaging of other organ systems, typically reserved for evaluating suspected ocular tumors, orbital masses, or unusual inflammatory conditions when other imaging methods such as ultrasound or MRI have left questions unanswered. The tracer distributes according to blood flow and tissue metabolism, and areas of abnormal uptake can point toward active disease processes within or around the eye.
Anatomy & Axis Detail
Lacrimal Ducts, Bilateral
The lacrimal ducts are the paired drainage channels, canaliculi, sac, and nasolacrimal duct, that carry tears from the eye into the nasal cavity. Imaging both sides at once is standard because obstruction is often unilateral and the contralateral duct serves as a built-in comparison for transit time. A radiotracer is instilled onto the ocular surface, typically as an eye drop, and its passage through the drainage system is followed on planar images over several minutes, a study often called a dacryoscintigram. Delayed or absent clearance points to a blockage, while its level along the duct can suggest whether the problem lies in the canaliculi, the sac, or the distal nasolacrimal segment, helping guide whether probing, dilation, or surgery is warranted.
Radionuclide: Technetium 99m (Tc-99m)
Technetium 99m (Tc-99m) is the most widely used radionuclide in Nuclear Medicine, valued for its short half-life and favorable gamma energy for imaging bone, cardiac, renal, and other organ systems. In this axis position it records that a technetium-based radiopharmaceutical was the tracer administered for the study, distinguishing it from the many other specific isotopes, such as thallium or iodine compounds, used for more specialized indications.
Coding & Documentation
Documentation supporting this code should show that a radioactive tracer was administered and that a single-plane gamma camera image of the orbit or eye was obtained and interpreted by the nuclear medicine or radiology physician. Coders need to confirm the target body part is genuinely the eye rather than a broader head and neck study that happens to include the orbit incidentally, since imaging of adjacent structures like the sinuses or brain falls under different body system values. A common assignment error is defaulting to a more frequently used body system code out of habit rather than verifying the specific anatomic target named in the report, or overlooking that a same-day CT or MRI of the orbit is a separate, non-nuclear-medicine procedure that should be coded independently.
Commonly Confused With
This procedure is sometimes confused with computed tomography or magnetic resonance imaging of the eye and orbit, which use different physical principles and belong to entirely different sections of the coding system rather than nuclear medicine. Within nuclear medicine itself, it can be confused with SPECT or PET imaging of the head that happens to capture the orbital region, but those use tomographic, multi-plane reconstruction techniques rather than the single flat image that defines planar imaging. The distinguishing factor is both the imaging modality, planar versus cross-sectional, and the specifically documented target of the eye rather than surrounding structures.